VERNON TOWNSHIP — “The goal is to save lives before breast cancer happens,” said Dr. Gurleen Pasricha, director of breast oncology at Meadville Medical Center’s Yolanda G. Barco Oncology Institute.
Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.
Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.